Memorandum

To: CIR Expert Panel Members and Liaisons
From: Jinqiu Zhu, PhD, DABT, ERT, CIR Toxicologist
Date: May 23, 2018
Subject: Revised Draft Hair Dye Epidemiology Document for Posting

Enclosed is the latest draft of the CIR Expert Panel Hair Dye Epidemiology document (Document). The enclosed draft is identified as hdepi062018rep. The previous draft was reviewed by the Panel at the December 2017 meeting. At the December meeting, the Panel requested the inclusion of additional studies regarding breast cancer incidences and concluded that the services of an expert epidemiologist, with experience specifically relevant to factors associated with breast cancer, should be retained to summarize the differences in study results. The enclosed evaluation, from Dr. Luigi Naldi, is identified as hdyepi062018com. Since then, however, two additional studies regarding the association between hair dyes and the risk of breast cancer, and a study regarding the potential association of prostate cancer with hair dye use, have been discovered. Dr. Naldi’s analysis and these additional studies are incorporated herein, highlighted in yellow, for the Panel’s consideration.

The Panel should review this Document, especially noting the additions, and decide if this Guidance Document is in agreement with their thinking and is ready to be finalized. If the Document is not considered to be ready for finalization, specific needs therein should be made evident.
Hair dyes may be broadly grouped into oxidative (permanent) and direct (semi-permanent) dyes. The oxidative
dyes consist of precursors mixed with developers to produce color, while direct dyes consist of preformed colors.

Epidemiology studies that seek to determine links, if any, between hair dye use and disease provide broad
information and have been considered by the CIR Expert Panel, although these studies do not specifically address the safety
of individual hair dye ingredients.

The following provides a brief summary of many relevant epidemiological studies that have been published since
about 2010, as well as older epidemiological studies that were included in comprehensive reviews, such as that published
by the International Agency for Research on Cancer (IARC) in 2010.

Conclusion

The CIR Expert Panel determined that the available hair dye epidemiology data do not provide sufficient evidence
for a causal relationship between personal hair dye use and cancer, based on the lack of strength of the associations and
inconsistency of the findings. In addition, the Panel noted that there was no consistent pattern of genotype/phenotype
influence on hair dye epidemiology findings.

Background

The CIR Expert Panel reviews new epidemiological studies addressing the personal use of hair dyes as these
studies become available. Table 1 summarizes the studies specifically addressing bladder cancer, lymphoma, and
leukemia and breast cancer. Relevant meta-analytical studies included here address glioma and breast cancer, in addition
to bladder and blood cancers. Occupation as a hairdresser, barber, or cosmetologist involves exposures to multiple
products used during work, making it difficult to use the results of such studies to inform the assessment of the risk, if any,
associated specifically with hair dyes. Accordingly, such studies are not summarized here.

The CIR Expert Panel considers that epidemiological studies, based on better information about exposure, can
provide more useful findings than other such studies. Rollison et al. (2006) noted that exposure assessments in hair dye
epidemiology studies ranged from minimal information (e.g., ever/never use) to subject-recalled information on type, color,
duration and frequency of use. These authors developed a scale from + to ++++ to score the quality of hair dye exposure
assessments in hair dye epidemiology studies. This scale was used to score the studies that are summarized in Table 1.

An IARC working group summarized the relevant epidemiology studies and observations on breast, bladder and
hematological cancers. The working group concluded that the data are of insufficient quality, consistency, or statistical
power to establish the presence or absence of a causal link between personal use of hair dyes and cancer. They also
concluded that the animal studies provided limited evidence for the carcinogenicity of hair colorants. Occupational
exposure during work as a hairdresser, barber, or beautician was also assessed. The working group found that exposures
from these occupations are probably carcinogenic, based on limited evidence of increased risk for bladder cancer in hair
dressers and barbers.

The studies herein result in either an odds ratio or a relative risk, two similar but not synonymous terms. An odds
ratio (OR) represents the odds that an outcome (e.g. cancer) will occur given a particular exposure, compared to the odds of
the outcome occurring in the absence of that exposure; whereas a relative risk (RR) is a measure of the risk of a certain
event happening in one group compared to the risk of the same event happening in another group. In cancer research,
ORs are most often used in case-control (backward looking) studies, and RRs are used in prospective (forward looking)
studies, such as cohort studies and clinical trials. An OR of 1 means that an exposure does not affects the odds of an
outcome (i.e. does not increase the risk of cancer), while a RR of 1 means there is no difference between two groups in
terms of risk following a particular exposure. However, either an OR or RR > 1 means the exposure may increase the risk of
disease.
**Bladder Cancer**

Turati et al. (2014) performed a meta-analysis of 15 case-control and 2 cohort studies. The abstracted information included the variables adjusted and/or used to match control subjects with cases. For example, 12 of the studies clearly adjusted for smoking; adjustment for smoking was not clear in 1 study. The pooled RR of bladder cancer incidence/mortality was 0.93 (95% confidence interval (CI) 0.83-1.05) for personal use of any type of hair dye, compared with no use, and similar results were obtained when the subjects were stratified by sex. The RR for personal use of permanent hair dyes from 7 of the studies was 0.92 (95% CI 0.77-1.09). Similarly, no association was found between bladder cancer and the duration or lifetime frequency of use of any type of hair dye or use of permanent hair dyes, compared with never used hair dyes. The RR for the use of dark-color hair dyes was 1.29 (95% CI 0.98-1.71).

Ros et al. (2012) performed a population-based case-control study of hair dye use and bladder cancer in the Netherlands. The subjects were 246 cases and 2587 controls; all of the subjects for which the analyses were performed were women (less than 5% of the men selected for the study reported ever using hair dyes). The hair dye exposure assessment was ++++ on the Rollison et al. (2006) scale. All analyses were adjusted for age and smoking status, duration and intensity. Additional adjustment for education level and other variables considered were not included in the final model because they did not change the standardized regression coefficient (β) by more than 10%. No association was found between bladder cancer and ever use of permanent hair dyes (OR 0.87; 95% CI 0.65-1.18) or temporary hair dyes (OR 0.77; 95% CI 0.58-1.02). Similarly, no association was observed when hair dye use was defined by type, duration or frequency of use, dye color, or extent of use or when the patients were stratified by aggressive and non-aggressive bladder cancers.

Koutros et al. (2011) conducted a population-based case-control study in Maine, Vermont, and New Hampshire. The subjects were 1,193 cases of urinary bladder cancer diagnosed from 2001 to 2004 (911 male and 282 female), and 1418 controls (1,039 male and 379 female). The hair dye exposure assessment was ++++ on the Rollison et al. (2006) scale. The hair dye models were adjusted for age, race, sex, and smoking status.

No association was found between ever/never use of hair dyes and bladder cancer – the OR and associated 95% CI for women was 0.7 (95% CI 0.5-1.0), and for men 0.7 (95% CI 0.4-1.0). Because of the excellent exposure assessment, the authors were able to examine subsets of the population studied. Women who used red hair colors, for example, exhibited an OR of 0.4 (95% CI 0.2-0.8), suggesting a significantly lower risk of bladder cancer associated with the use of such hair dyes. A similar lower risk of bladder cancer was reported for women who used hair dyes for a duration between 10 and 19 years (OR 0.5; 95% CI 0.27-0.79). As the data were further analyzed, the authors considered women with and without college degrees. Women without college degrees who used permanent hair dyes exclusively, for example, had a significantly lower risk of bladder cancer (OR 0.5; 95% CI 0.4-0.7). Exclusive use of permanent hair dyes by women with college degrees was associated with a significantly higher risk of bladder cancer (OR 4.9; 95% CI 1.7-14.6). No statistically-significant interactions with hair-dye use were found when the data were stratified by state of residence, hair-dye product type, smoking, age at diagnosis/interview, or disease aggressiveness in the female subjects.

Shakhssalim et al. (2010) reported a population-based case-control study of several likely risk factors for bladder cancer in Iran with 692 cases and 692 controls. Cases were identified using the Iranian cancer registry. The hair dye exposure assessment was a + on the Rollison et al. (2006) scale. The OR for hair dye use and bladder cancer was 1.81 (95% CI 1.08-3.06). After adjustment for cigarette smoking, the OR was 1.99 (95% CI 1.02-3.82). When women and men were analyzed separately, no significant association with hair dye use and bladder cancer was found.

**Prostate Cancer**

Tai et al. (2016) reported a hospital-based case-control study of hair dye use and prostate cancer in Taiwan. The subjects were 296 cases with newly diagnosed prostate cancer and 296 age-, ethnicity-, and hospital-matched controls. Information on hair dye use was obtained through a standardized questionnaire. The prevalence of hair dye use was higher in the cases than the controls (95/296 = 32.1% vs. 64/296 = 21.6%, p < 0.05), and the hair dye users had increased odds of prostate cancer compared with the non-users (adjusted OR 2.15; 95% CI 1.32-3.57). The study found personal hair dye use increased risk of prostate cancer with a dose-response effect. Meanwhile, to determine the rate of prostate cancer survival, another 608 incident prostate cancer cases were investigated. Of the 608 cases, 26.4% (161/608) reported having used hair dyes. The use of hair dye did not affect cumulative incidence estimates of prostate cancer-specific deaths (p=0.753).
This report was the first to show a positive association between personal hair dye use and risk of prostate cancer, revealing a dose-response relationship in terms of duration and frequency; however, cumulative exposure dose, a critical indicator to estimate a dose-response effect, was not assessed. The external validity of this study has been questioned. Other studies targeted on hairdressers observed no increased risk of prostate cancer. While Tai et al.’s findings are limited and do not represent evidence for the presence of a cause-effect relationship, further investigations may be warranted.

**Lymphoma and Leukemia**

Towle et al. (2017) conducted a meta-analysis of 20 case-control studies of leukemia. The RRs for the associated risk of leukemia were: with permanent hair dye use RR = 1.19 (95% CI 1.07–1.33), with dark hair dye use RR = 1.29 (95% CI 1.11–1.50), with hair dye use among males RR = 1.42 (95% CI: 1.01–2.00), with hair dye use pre-1980 RR = 1.49 (95% CI: 1.21–1.83), and with hair dye use for longer than 15 years RR = 1.35 (95% CI: 1.13–1.62). Overall, findings suggest that ever use of hair dye is not a significant risk factor for leukemia.

Parodi et al. (2016) performed a population-based case-control study of leukemia and non-Hodgkin’s lymphoma (NHL) in Italy. The analysis was restricted to women in the population studies because too few of the men reported any hair dye use. There were 161 cases (120 lymphoid and 41 myeloid) and 84 controls among the women. The evaluation of hair dye exposure was a + on the Rollison et al. (2006) scale, because only duration of hair dye use < 15 years vs. ≥ 15 years was evaluated. In a multivariate analysis, the OR was 2.3 (95% CI 1.0-4.9), with p = 0.036 for a trend, for NHL in women using hair dye for at least 15 years. No association was found between lymphoid malignancies and tobacco smoking or the consumption of alcoholic beverages in this study.

Linet et al (2014) conducted a meta-analysis of 19 case-control studies of NHL subtypes, focusing on follicular lymphoma (FL). No associations between FL and hair dye use type, duration, or frequency were found in this study, except for a modest increase in women who used hair dyes before 1980 (OR = 1.4; 95% CI 1.10-1.78). Many oxidative hair dye products were reformulated in the early 1980s in the U.S. to eliminate ingredients that produced tumors in animal bioassays. In comparison, the risk of FL in women was associated with current cigarette smoking, trending higher with increasing duration of smoking.

Cerhan et al. (2014) performed a meta-analysis of 19 case-control studies of NHL subtypes, focusing on diffuse large B-cell lymphoma (DLBCL). There were no overall and sex- or age-specific associations between DLBCL and hair dye use, based on the basic adjusted model results of this study. The OR for mediastinal DLBCL was 4.97 (95% CI 1.63-15.15) for use of hair dyes for at least 20 years, compared with never used hair dyes. Using hair dyes for at least 20 years was not associated with DCBCL at other anatomical sites, including the central nervous system (CNS), testis, gastrointestinal tract, and skin. Use of hair dyes for less than 20 years was not associated with DLBCL at any site. In comparison, smoking was associated with CNS, testicular and cutaneous DLBCLs in this study.

Salem et al. (2014) conducted a hospital-based case-control study of leukemia and lymphoma in Egypt. There were 130 cases, including 23 cases of chronic lymphocytic leukemia (CLL) and 107 cases of NHL, and 130 age- and sex-matched controls. The evaluation of hair dye exposure was a + on the Rollison et al. (2006) scale. In a univariate analysis, no statistically significant association was found between these lymphoproliferative disorders and history of using hair dyes, family history of cancer, exposure to X-rays, or smoking (χ², p>0.05).

Lv et al. (2010) conducted a hospital-based case-control study of myelodysplastic syndromes (MDSs) in China. There were 403 cases and 806 controls, and the evaluation of hair dye exposure was a ++ on the Rollison et al. (2006) scale. In a univariate analysis, the OR for hair dye use (≥ 2 times per year) and all MDSs was 1.46 (95% CI 1.03-2.07). In a multivariate analysis performed to adjust for potential confounding factors, the OR was not statistically significant (OR 1.31; 95% CI 0.88-1.93). In comparison, smoking was associated with the development of MDSs in the univariate analysis and with refractory anemia with excess blasts (RAEB) in both the univariate and multivariate analyses.

Wong et al. (2010) conducted a hospital-based case-control study of NHL in Shanghai. There were 649 cases and 1,298 controls, and the evaluation of hair dye exposure was a ++ on the Rollison et al. (2006) scale. No increased risk of NHL was reported (OR 0.93; 95% CI 0.75-1.16). For CLL and small lymphocytic lymphoma (SLL), the authors reported a significantly lower risk associated with hair dye use (OR 0.37; 95% CI 0.18-0.76). In comparison, alcohol...
consumption and cigarette smoking were not associated with NHL in this study, although smoking \( \leq 20 \) years (but not \( > 20 \) years) was associated with precursor B-cell neoplasms.

Chang et al. (2010) re-evaluated tissue samples from a NHL case-control study in males from Iowa and Minnesota using FISH (fluorescence in situ hybridization) cytogenetic technique to evaluate both \( t(14;18) \)-positive and \( t(14;18) \)-negative NHL subtypes and IHC (immunohistochemistry) assays to evaluate expression of the anti-apoptotic protein bcl-2.21 There were 8 \( t(14;18) \)-positive, 12 \( t(14;18) \)-negative, 20 bcl-2 positive, and 4 bcl-2 negative NHL cases and 58 control subjects in the subpopulation tested (i.e., men having used hair dye at least once a month for at least one year, or occupational exposure to hair dyes on any job held for at least a year). The evaluation of hair dye exposure scored + on the Rollison et al. (2006) scale. Adjusting for age, state and proxy status (i.e., whether or not next-of-kin proxies were interviewed), a statistically-significant association between ever/never use of hair dyes and \( t(14;18) \)-negative NHL (OR 2.9; 95% CI 1.6-5.0) and bcl-2 positive NHL (R 2.2; 95% CI 1.4-3.4), but not with \( t(14;18) \)-positive NHL (OR 1.3; 95% CI 0.6-2.6) or bcl-2 negative NHL (OR 1.4; 95% CI 0.5-3.8). Similarly, smoking was associated with \( t(14;18) \)-negative NHL, but not clearly associated with \( t(14;18) \)-positive NHL, bcl-2 negative NHL, or bcl-2 positive NHL in this study.

Wong et al. (2009) reported a hospital-based case-control study of acute myeloid leukemia (AML) in Shanghai.22 There were 722 cases and 1,444 age- and sex-matched controls. The evaluation of hair dye exposure was a ++ on the Rollison et al. (2006) scale. The study found no increase in the risk of AML and personal use of hair dyes; The OR was 0.98 (95% CI 0.8-1.2). In contrast, there was an association between AML and smoking, particularly among the male subjects, as well as alcohol consumption and a low level of education in this study.

**Glioma**

Shao et al. (2013) performed a meta-analysis of 4 case-control and 2 cohort studies of personal hair dye use and the incidence of gliomas.23 Matching or adjustment for age and sex was performed in all 6 studies included in this meta-analysis, and for smoking in 2 of the 6 studies. The most adjusted risk estimates were included, and the raw data were used when adjusted estimates were not available. Summary RRs for ever use of any hair dyes were 1.132 (95% CI 0.887-1.446) for all studies, 1.291 (95% CI 0.937-1.777) for case-control studies, and 0.903 (95% CI 0.774-1.054) for cohort studies. Similar results were obtained when the subjects were stratified by geographic regions and sex. No significant associations were found among the studies that evaluated permanent hair dye use and duration of any hair dye use.

**Breast Cancer**

Llanos et al. (2017) conducted a population-based case-control study of hair dye use and breast cancer in African American and European American women in the Women’s Circle of Health Study (WCHS).24 The subjects were 1508 African American and 772 European American cases (52±10.7 and 52.0±10.0 years old, respectively) and 1290 African American and 715 European American age- and county-matched control subjects (50.9±10.3 and 49.8±8.7 years old, respectively). The evaluation of hair dye exposure was +++ on the Rollison et al. (2006) scale. The final multivariate model included age, education, body-mass index (BMI), family history of breast cancer, and oral contraceptive use; age at menarche, parity and hormone-replacement therapy were omitted based on statistical analysis (p > 0.1). In the multivariate analysis, the ORs for breast cancer were 1.52 (95% CI 1.21-1.91), 1.30 (95% CI 1.03-1.63), and 2.21 (95% CI 1.26-3.86), respectively, for African American women who reported using dark permanent hair dyes, African American women who typically had their hair dyed in a salon (rather than using a home kit), and European American women who had a history of both hair dyes and chemical hair relaxers, compared with matched controls who never used hair dyes. Use of dark dyes among both African American and European American women and dual use of hair dyes among European women were associated with estrogen-receptor positive (ER+) breast cancer (OR=1.72, 95% CI 1.30-2.26; 1.36, 95% CI 1.01-1.84), and 2.40, 95% CI 1.35-4.27, respectively). In this study, women who started using hair dyes before 1980 were not distinguished from women who started in 1980 or thereafter.

Heikkinen et al. (2015) performed a population-based case-control study of hair dye use and breast cancer in Finland.25 The subjects were 6,567 breast cancer patients and 21,598 age-matched controls. The evaluation of hair dye exposure was a +++ on the Rollison et al. (2006) scale. The multivariate model was adjusted for parity, age at first birth, family history of breast cancer, menarche age, use of hormonal contraceptives, physical activity, alcohol use, BMI and education. The OR for breast cancer was 1.23 (95% CI 1.11-1.36) for women who ever used hair dyes, compared with
those who never used hair dyes; the analogous ORs were 1.28 (95% CI 1.10-1.48) for women born before 1950 and 1.14 (95% CI 0.85-1.54) for women born in 1960 or later. Logistical regression analysis indicated that there was a statistically-significant trend (p=0.005) in the ORs calculated for number of hair dye episodes (1.07 for 1-2 episodes vs. 1.35 for 35-89 episodes). The ORs did not change when smoking was included in the multivariate analysis.

Takkouche et al. (2005) conducted a meta-analysis of epidemiological studies of hair dye use and cancer risks, including 12 case-control studies and 2 cohort studies of breast cancer. The adjustment, matching and/or restriction factors included age in all 14 studies, smoking in 6 studies, education in 2 studies, and alcohol consumption in 1 study evaluated in this meta-analysis. The random-effects pooled RR estimated from all 14 studies for ever users was 1.06 (95% CI 0.95-1.18). Likewise, ORs calculated for ever used vs. never used hair dyes specifically from case-control studies, cohort studies, or permanent hair dye use only, or for intensive exposure (i.e., more than 200 lifetime exposures) were not statistically significantly.

Mendelsohn et al. (2009) conducted a prospective cohort study of ever dye use and cancer risks of women in China, including cases of breast cancer with 234 hair dye users and 358 non-users. The results were derived using Cox proportional hazards models, adjusted for age, education and smoking duration. The average number of person years was 7.31. The RR for breast cancer was 0.93 (95% CI 0.78-1.09) for women who ever used hair dyes, compared with those who never used hair dyes. No significant association was observed between hair dye use and the risk of breast cancer. Stratification by menopausal status indicated no association between breast cancer and hair dye use in either pre- or post-menopausal women.

Kinlen et al. (1977) conducted a case-control study of 191 breast cancer patients interviewed in a hospital in 1975-1976 in Oxford, UK, with 561 aged matched controls without cancer (within three years), marital status, and social class. Seventy-three cases and 213 controls had used permanent or semi-permanent hair dyes, giving an RR of 1.01. There was no evidence of an increasing risk for breast cancer with increasing duration of use of hair dyes or with use beginning more than four or more than nine years before diagnosis.

Stavraky et al. (1979) conducted a case-control study of 50 breast cancer patients at a cancer treatment center with 100 hospitalized controls in London, Ontario, and 35 breast cancer cases with 70 neighborhood controls in Toronto, Ontario, with respect to hair-dye use. The RR for breast cancer from use of permanent hair dyes (at any time) were 1.3 (95% CI 0.6-2.5) in London and 1.1 (0.5-2.4) in Toronto. Further statistical analyses, allowing for smoking habits, family history of cancer and age at first birth, showed no significant relationship between hair-dye use and breast cancer incidence.

Koenig et al. (1991) conducted a case control study of 398 breast cancer patients at a screening center between 1977 and 1981 in New York City, with 90 randomly selected, age matched controls. The OR for breast cancer from use of permanent hair dyes (at any time) was 0.8 (95% CI 0.6-1.1). There was also no evidence of a trend in risk with increasing number of hair dye uses (38% of the subjects had used hair dye at least 100 times, while 77% had used hair dyes at least once). An analysis of breast cancer risk from 5 or more years of work as a beautician was also compared. Although personal hair dye use was unrelated to breast cancer risk, the OR for beauticians was 3.0 (95% CI 1.1-7.8).

According to an analysis by Naldi (2018), the available evidence linking hair dye use and breast cancer is limited. Based on the available human evidence, personal use of hair dyes is unlikely to be an important risk factor for breast cancer. However, concerns are warranted on two recent studies that pointed to an increased risk in different ethnic groups and populations, African Americans, White American women, and Finnish women. One systematic review, two case-control studies, and one cohort study, all published after 2004, were included in Naldi’s evaluation. Strengths of these epidemiologic studies include evaluation of a variety of populations, while limitations of some of the studies include lack of specificity for type of hair dyes used (oxidative versus non-oxidative) and details on color, type, or duration of use. In addition, it is worthy to note that hair dye formulations have changed over time, and they differ based on the region of the world in which they are produced and sold. Hence the specific product used and the timing of use should be better considered. Comments from Naldi on the recent epidemiology studies that investigated the association between hair dye use and breast cancer are summarized below.

1) The systematic review (Takkouche et al., 2005) summarizes results of studies conducted from 1966 up to January 2005, and includes twelve case-control studies, which involved a total of 5019 cases and 8486 controls, and two cohort studies which recruited a total of 1135 incident cases of breast cancer. The pooled RR of breast cancer was close to 1 and nonsignificant when comparing ever use vs. never use of hair
dyes. No significant increased risk was documented when considering intensive exposure or restricting analyses to the use of permanent dyes only. It is noted that, giving the largely prevalent use of hair dyes in the population, frequency of use rather than simple distinction between users and nonusers, would be relevant to consider.

2) In the cohort study (Mendelsohn et al., 2009) conducted in the framework of the Shanghai Women's Health Study, a total of 75221 women completed a baseline survey between 1996 and 2000 and were followed up to December 2005. In the sample, 29076 women (39.6%) reported ever using hair dye and a total of 358 incident cases of breast cancer were identified. The RR for breast cancer in hair dye users vs non-users, adjusted by age, education and smoking, was close to 1. No relation was documented between duration of hair dye use and risk of cancer. However, information on the type of hair dye used (permanent vs semi-permanent) and about the frequency of use was not provided. Moreover, exposure was assessed over the 3 years preceding the baseline interview only. Hence, a potential misclassification may tend to minimize the presence of association regardless of whether the association is positive or negative (i.e., bias toward the null).

3) In the case-control study (Llanos et al., 2017) conducted in the metropolitan New York City area and in ten counties in New Jersey, involving both African Americans and White women, a total of 2,280 cases and 2,005 controls were enrolled. Final OR estimates were adjusted by age, education, body mass index, family history of breast cancer, and oral contraceptive use. Overall, ever use of hair dyes and duration of use were not significantly associated with increased cancer risk in both African Americans and Whites. Among African Americans, an increased risk of breast cancer was documented for the use of dark hair dye shades, and for salon application of dyes, adjusted OR being 1.51 (95% CI, 1.20-1.9) and 1.26 (95% CI, 1.00-1.58), respectively. In Whites, an increased risk was documented for dual use of relaxers and hair dyes with OR 2.40 (95% CI 1.35-4.27), the wide CI reflecting the limited number of exposed women. When considering the estrogen receptor status of cancer, the risk of estrogen positive breast cancer was increased in African Americans with a higher frequency of hair dye use (OR 1.36, 95% CI 1.01-1.84) and in Whites with the use of dark hair dye shades (OR 1.54, 95% CI, 1.01-2.33). These differences in risk profile between African Americans and Whites are not easy to reconcile. They may reflect different patterns of use, or represent chance effects due to multiple testing. Replication of results by an independent study is needed.

4) The population based case-control study in Finland (Heikkinen, et al., 2015) recruited a total of 6,567 breast cancer patients diagnosed between 2000 and 2007 and 21,598 age-matched controls. When calculating ORs, potential confounding factors, namely parity, age at first birth, family history of breast cancer, menarche age, use of hormonal contraceptives, physical activity, alcohol use, body mass index and education, were included in a stepwise regression model. The OR increased significantly with the increase in number of reported hair dye episodes, from 1.07 with 1–2 dye episodes up to 1.31 for 35–89 dye episodes. Early age at first dye (20–29 years) was associated with higher odds of breast cancer when compared to late age at first dye (40 years or later) (OR 1.14, 95% CI: 1.05–1.25). When considering ever use vs. non-use, the ORs were increased with all the different types of hair dyes, the highest estimates being obtained for women who reported to have used temporary and/or semi-permanent dyes, ORs being 1.32 (95% CI: 1.16–1.52) and 1.31 (95% CI: 1.17–1.46), respectively.

The following two studies were discovered after Naldi’s analysis. While these studies were not subjected to the same valuation, these results seem to share the same limitations, such as a lack of specificity for type of hair dyes used (oxidative versus non-oxidative) and details on color, type, or duration of use.

Dianatinasab et al. (2017) conducted a hospital-based case-control study of breast cancer on 1052 women in Iran. There were 526 newly diagnosed breast cancer cases, with 526 age-matched controls randomly selected in Namazi Hospital between November 2014 and March 2016. The study showed that multiple factors contribute to the risk of breast cancer, such as hair coloring, stress, and smoking. The OR of breast cancer from hair dye use on a regular basis compared to no use was 1.93 (95% CI, 1.41-2.62).

Gera et al. (2018) conducted a meta-analysis of epidemiological studies that investigated the association between hair dye use and breast cancer, including eight case-control studies published between 1980 and 2017 with a total of 38037 participants. Among them, six studied have already been evaluated in the meta-analysis conducted by Takkouche et al.
in addition to Dianatinasab et al.’s report mentioned above. However, the other eight studies covered by Takkouche et al.’s paper were excluded from this meta-analysis. Note that six of these eight excluded studies did not suggest an increased risk of breast cancer in users of hair dye. The exclusion criteria includes, but is not limited to: (1) breast cancer was not the sole focus of investigation (i.e., studies examining any non-breast related cancer as a case were excluded); (2) studies failed to provide overall or accurate RR and 95% CI; (3) studies failed to adequately control for confounding factors; (4) studies with small sample size. Using a random effects model and the Duval and Tweedie’s trim and fill procedure to adjust for publication bias in the presence of between studies heterogeneity, such meta-analysis showed that RR for women using hair dyes was 1.188 (95% CI 1.03-1.37), which indicates an 18.8% increased risk of future development of breast cancer among hair dye users. While these findings do not represent evidence for the presence of a cause-effect relationship, further investigations may be warranted.

Genetic Polymorphisms

NAT1, NAT2, GSTM1, and GSTT1 Genotype/Phenotype

The study by Koutros et al. (2011) is the latest in a series of studies that have examined the influence of genotype and phenotype of liver enzymes that may activate or inactivate potential carcinogens.

NAT1 and NAT2 genes encode arylamine N-acetyltransferases that can deactivate (or, less commonly, potentially activate) arylamine and hydrazine chemicals. Polymorphisms in these genes determine, in part, the liver-function phenotypes. Human populations segregate into rapid, intermediate, and slow acetylator phenotypes. N-acetylation is a major route of biotransformation of aromatic amine compounds, including those found in hair dyes.

The GSTM1 gene encodes a cytoplasmic glutathione S-transferase that belongs to the µ class, which functions in the detoxification of electrophilic compounds (including carcinogens, therapeutic drugs, environmental toxicants, and products of oxidative stress) through conjugation with glutathione. The GSTT1 gene encodes the glutathione S-transferase that belongs to the θ class, which catalyzes the conjugation of reduced glutathione to a variety of electrophilic and hydrophobic compounds. Genetic polymorphisms in GSTM1 and GSTT1 also may affect the metabolism of the constituents of hair dyes.

Koutros et al. (2011) performed genotyping for NAT2, NAT1, GSTM1, and GSTT1. The hair dye models were adjusted for age, race, sex, and smoking status. An increased risk of bladder cancer was reported primarily among exclusive users of permanent dyes who had NAT2 slow-acetylation phenotypes, compared to never users of dye with NAT2 rapid/intermediate-acetylation phenotypes. This increase was observed in females with a college degree, but the difference was not statistically significant. The authors concluded that NAT1, GSTM1, and GSTT1 genotypes did not appear to be important modifiers of the association between ever, permanent, or exclusive permanent hair dye use and bladder cancer.

Gago-Dominguez et al. (2003) reported that individuals with the NAT2 slow-acetylator phenotype who exclusively used permanent hair dyes had an increased risk of bladder cancer (OR 2.9; 95% CI 1.3-7.5) after adjustment for cigarette smoking, compared to individuals with the NAT2 rapid-acetylator phenotypes (OR 1.3; 95% CI 0.6-2.8). The NAT*10 allele contains an altered polyadenylation signal that has been associated with elevated DNA adduct levels and greater risk of bladder cancer in other studies. Individuals with a NAT1*10 genotype who were non-smokers and used permanent hair dyes exclusively had an OR of 1.0 (95% CI 0.2-4.3), and those with a non-NAT1*10 genotype had an OR of 6.8 (95% CI 1.7-27.4) in this study.

Kogevinas et al. (2006) evaluated the association of hair dye use with bladder cancer among females in a case-control study that also examined the effect of hair-dye use among genetic subgroups. ORs were estimated after adjustment for age, region, and smoking. No statistically significant differences in bladder cancer incidence were noted as a function of any of the genotypes examined, including those with slow- or intermediate/rapid-NAT2 acetylator phenotypes. For NAT2 slow-acetylator phenotypes, the OR was 0.6 (95% CI 0.3-1.4), and for NAT2 rapid/intermediate phenotypes, the OR was 0.9 (95% CI 0.3-2.6). Individuals with a NAT1*10 genotype had an OR of 2.9 (95% CI 0.7-11.6), and those with non-NAT1*10 had an OR of 0.6 (95% CI 0.2-1.6). These findings were directionally opposite to those of Gago-Dominguez et al. (2003).
Morton et al. (2007) conducted a population-based case-control study of NHL. Subjects were identified among residents of 4 Surveillance Epidemiology and End Results (SEER) registries (Iowa, Los Angeles County, and metropolitan Detroit and Seattle). There were 101 cases and 98 control subjects reporting no use of hair coloring products and 509 cases and 413 control subjects among the women reporting use of such products, in the population studied. There were 317 cases and 269 control subjects reporting the use of hair dyes before 1980 and 192 cases and 148 controls reporting hair dye use in 1980 or thereafter. The risk estimates were adjusted for age, sex, race and SEER area; education, smoking status, history of farming, having a first-degree relative with a history of NHL or lymphoproliferative malignancy were excluded from the final models because these factors did not materially alter (> 10%) the parameter estimates.

Among the women who started using permanent, intense-tone hair dyes before 1980, those with the NAT2 slow-acetylator phenotype (23 cases/14 controls) or who had no copies of the NAT1*10 allele (26 cases/16 controls) did not have an increased risk of NHL (OR 1.5; 95% CI 0.6-3.6 and OR 1.5; 95% CI 0.7-3.3, respectively). Likewise, women in this subpopulation with 1 or 2 copies of the NAT1*10 allele (22 cases/10 controls) did not have an increased NHL risk (OR 2.5; 95% CI 0.9-7.6, respectively). However, women with the NAT2 rapid/intermediate-acetylator phenotype who started using such dyes before 1980 (25 cases/11 controls) did exhibit a potentially increased NHL risk (OR 3.3; 95% CI 1.3-8.6). There was no evidence of increased risk among women who began using hair dyes after 1980.

Zhang et al. (2009) re-evaluated data from a case-control study of NHL in Connecticut (Zhang et al. 2004) to consider NAT1 and NAT2 genotype/phenotype and 17 other single nucleotide polymorphisms (SNPs). The subjects, including 461 cases and 535 control subjects, were identified from the Yale Comprehensive Cancer Center’s Rapid Case Ascertainment Shared Resource (RCASR). Potentially confounding variables included in the final model were age and race. Adjustment for cigarette smoking, alcohol consumption, and farming history were not included in the final models because these factors did not materially alter the parameter estimates.

With the exception of FL, none of the different individual genes examined was associated with a statistically-significant change in the risk of NHL for any of the NHL subtypes considered. The exception was a statistically-significant increase in the risk of FL in women with rapid/intermediate NAT2 phenotypes who started to use hair dye before 1980, compared with women who never used hair dye (OR 2.8; 95% CI 1.1-7.2; 24 rapid/intermediate acetylator cases vs. 79 control subjects). In women who carried the CYP2C9 allele (TT or CT genotypes) and started to use hair dyes before 1980, there was an increased risk of NHL in general (OR 2.9; 95% CI 1.4-6.1; 58 cases, 43 control subjects) and the follicular lymphoma subtype specifically (OR 6.3; 95% CI 1.6-24.7; 20 cases, 43 control subjects), compared with women who never used hair dyes and women who started using hair dyes in 1980 or thereafter. No association evident in women who carried the CYP2C9 allele (TT or CT genotypes) and started using hair dyes in 1980 or thereafter (23 cases, 46 control subjects), compared with women who carried this allele and never used hair dyes (OR 1.0; 95% CI 0.4-2.3; 23 cases, 46 control subjects).

DNA Repair-Enzyme Genes

Guo et al. (2014) investigated the interaction between polymorphisms in DNA repair genes and hair dye use with NHL in a population-based case-control study in Connecticut. The study population from which the subjects were drawn was the same as that of Zhang et al. (2009) study summarized above, including 461 cases and 535 control subjects identified from the Yale Comprehensive Cancer Center’s RCASR. The subjects included 518 NHL cases and 597 age-matched controls. All subjects were genotyped for 24 single nucleotide polymorphisms (SNPs) in 16 DNA repair-enzyme gene polymorphisms. The hair dye exposure assessment was ++++ on the Rollison et al. (2006) scale. All of the models were adjusted for age, race, and smoking status. The risk of FL, but not DLBCL, was statistically-significantly elevated in women with any one of 10 of the 24 SNPs and who used hair dye before 1980, compared to those who never used hair dyes; the ORs ranged from 1.93 (95% CI 1.00-3.72; 15 cases and 70 control subjects with EEC1rs3212961 CC) to 3.28 (95% CI 1.27-8.50; 7 cases and 110 control subjects with BRCA2rs144848 AC+CC). In addition, there was a statistically-significant interaction between hair dye use before 1980 and NHL in women with one of these 10 SNPs (1.88 (95% CI 1.26-2.80; 146 cases and 100 control subjects with WRNrs1346044 TT). There was no association between NHL, FL, or DLBCL in women who began using hair dyes after 1980.
Table 1. Hair Dye Epidemiology Studies considered by the CIR Expert Panel.

<table>
<thead>
<tr>
<th>Study Type/Methodology</th>
<th>Results</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bladder Cancer</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Population-based case-control study in the Netherlands. Cases diagnosed between 1975 and 2009 for a total of 246 female cases with 2587 female controls; Analyses were not performed for the men selected for the study because less than 5% reported ever using hair dyes.</td>
<td>No association between bladder cancer and ever/never use of permanent hair dyes – permanent OR 0.87 (95% CI 0.65-1.18); temporary OR 0.7 (95% CI 0.58-1.02)</td>
<td>Ros et al (2012)7</td>
</tr>
<tr>
<td>Population-based case-control study in Maine, Vermont, and New Hampshire. Cases diagnosed 2001 to 2004 for a total of 1193 cases (911 male and 282 female) with 1418 controls (1039 male and 378 female). Genotyping done for NAT2, NAT1, GSTM1, and GSTT1.</td>
<td>No association between ever/never use of hair dyes and bladder cancer – women OR 0.7 (95% CI 0.5-1.0); men OR 0.7 (95% CI 0.4-1.0). No association between hair dye use, NAT2 phenotype or NAT1 genotype and bladder cancer risk. Increased risk of bladder cancer with permanent hair dye use in a subgroup of women with a college degree, but no dose-response for color, duration of use, or total lifetime uses. NAT2 phenotype was associated with a suggestive, but not statistically significant, increased risk when college-degreed women were stratified by education – this was based on 15 cases and 6 controls.</td>
<td>Koutros, et al. (2011)8</td>
</tr>
<tr>
<td>Population-based case-control study of bladder cancer in Iran with 692 cases and 692 controls (identified using the Iranian cancer registry).</td>
<td>Overall (male and female) OR for hair dye use and bladder cancer was 1.99 (95% CI 1.02-3.82). When women and men were analyzed separately, no significant association with hair dye use and bladder cancer was reported.</td>
<td>Shakhssalim et al. (2010)9</td>
</tr>
<tr>
<td><strong>Prostate Cancer</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hospital-based case-control study of bladder cancer in Taiwan with 296 cases and 296 controls. Another 608 incident prostate cancer cases were investigated to determine the rate of prostate cancer survival.</td>
<td>The prevalence of hair dye use was higher in the cases than the controls (95/296 = 32.1% vs. 64/296 = 21.6%, p &lt; 0.05), and the hair dye users had increased odds of prostate cancer when compared with the non-users (adjusted OR 2.15; 95% CI 1.32–3.57). Personal hair dye use increased risk of prostate cancer with a dose-response effect. Of the 608 cases, 26.4% (161/608) reported having used hair dyes. The use of hair dye did not affect cumulative incidence estimates of prostate cancer-specific deaths (p=0.753).</td>
<td>Tai et al. (2016)10</td>
</tr>
<tr>
<td><strong>Lymphoma and Leukemia</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cohort or case-control study of leukemia in North America, Europe and Asia.</td>
<td>Mutivariate analysis: Based on 20 studies, ever use of any type of personal hair dye was associated with a non-statistically significant increased risk of leukemia, when compared to no use of hair dye (meta-RR=1.09; 95% CI 0.97–1.22). A model restricted to case-control studies yielded a statistically significant increased RR of 1.13 (95% CI 1.00–1.28), while a model including cohort studies yielded an RR of 1.00 (95% CI 0.85–1.19). When restricted to studies that adjusted for smoking history, use of any hair dye was not associated with leukemia (RR= 0.99; 95% CI 0.76–1.29).</td>
<td>Towle et al. (2017)11</td>
</tr>
<tr>
<td>Study</td>
<td>Results</td>
<td>References</td>
</tr>
<tr>
<td>---------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>Population-based case-control study of leukemia and non-Hodgkin’s lymphoma (NHL) in Italy. There were 161 cases (120 lymphoid and 41 myeloid) and 84 randomly-selected controls among women in the population studied.</td>
<td>Multivariate analysis: Hair dye use for at least 15 years was associated with NHL (OR=2.3; 95% CI 1.0-4.9), but hair dye use for less than 15 years was not associated with NHL (OR=1.4; 95% CI 0.6-3.1). Leukemia was not associated with using hair dye for at least 15 years (OR=2.7; CI 0.9-7.9) or for less than 15 years (OR=2.7; CI 0.9-8.4).</td>
<td>Parodi et al. (2016)14</td>
</tr>
<tr>
<td>Hospital-based case-control study of lymphoproliferative cancers in Egypt. There were 130 cases (107 NHL and 23 chronic lymphocytic leukemia) and 130 age- and sex-matched controls.</td>
<td>Multivariate analysis: No increase in the risk of lymphoproliferative disorders with history of using hair dyes (χ², p&lt;0.05).</td>
<td>Salem et al. (2014)18</td>
</tr>
<tr>
<td>Hospital-based case-control study of myelodysplastic syndromes (MDS) in China. There were 403 cases and 806 controls.</td>
<td>Univariate analysis: OR for hair dye use (≥2 times per year) and all MDS was 1.46 (95% CI 1.03-2.07). Multivariate analysis: OR was 1.31 (95% CI 0.88-1.93).</td>
<td>Lv et al. (2010)19</td>
</tr>
<tr>
<td>Hospital-based case-control study in Shanghai of NHL. There were 649 cases and 1298 controls.</td>
<td>No increased risk of NHL, with an OR of 0.93 (95% CI 0.75-1.16). For chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), the authors reported a significantly lower risk associated with hair dye use with an OR of 0.37 (95% CI 0.18-0.76).</td>
<td>Wong et al. (2010)20</td>
</tr>
<tr>
<td>Re-evaluated tissue samples from an NHL case-control study in males from Iowa and Minnesota using FISH (fluorescence in situ hybridization) cytogenetic technique to evaluate both t-positive and t-negative NHL subtypes.</td>
<td>An association between ever/never use of hair dyes and t(14;18)-negative NHL (OR 2.9; 95% CI 1.6-5.0) and bcl-2 positive NHL (R 2.2; 95% CI 1.4-3.4), but not with t(14;18)-positive NHL (OR 1.3; 95% CI 0.6-2.6) or bcl-2 negative NHL (OR 1.4; 95% CI 0.5-3.8).</td>
<td>Chang et al. (2010)21</td>
</tr>
<tr>
<td>Hospital-based case-control study of acute myeloid leukemia (AML) in Shanghai, China. There were 722 cases and 1,444 controls.</td>
<td>No increase in the risk of AML with personal use of hair dyes; OR = 0.98 (95% CI 0.8-1.2).</td>
<td>Wong et al. (2009)22</td>
</tr>
</tbody>
</table>

**Breast Cancer**

<table>
<thead>
<tr>
<th>Study</th>
<th>Results</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population-based case-control study of breast cancer in African American and European American women in New York city and 10 counties in New Jersey. There were 1508 African American and 772 European American cases and 1290 African American and 715 European American frequency-matched (by age and county of residence) control subjects.</td>
<td>Increase in the odds of breast cancer in African American women who reported using dark permanent hair dyes (1.52; 95% CI 1.21-1.91), African American women who typically had their hair dyed in a salon (1.30; 95% CI 1.03-1.63), and European American women who had a history of both hair dyes and chemical hair relaxers (2.21; 95% CI 1.26-3.86). Women who started using hair dyes before 1980 were not distinguished from women who started in 1980 or thereafter.</td>
<td>Llanos et al. (2017)34</td>
</tr>
<tr>
<td>Population-based case-control study of breast cancer in Finland. There were 6,567 cases and 21,598 age-matched controls.</td>
<td>Increase in the odds of breast cancer in women who ever used hair dyes, compared with those who never used hair dyes (OR=1.28; 95% CI 1.10-1.48). Statistically significant trend in ORs for cumulative use of hair dyes (1.07 and 1.31 for 1-2 episodes and 35-89 episodes, respectively).</td>
<td>Heikkinen et al. (2015)35</td>
</tr>
<tr>
<td>Prospective population-based cohort study of breast cancer in China. Cases of breast cancer include 234 hair dye users and 358 non-users.</td>
<td>No increase in the relative risk of breast cancer in women who ever used hair dyes, compared with never used hair dyes (RR=0.93; 95% CI 0.78-1.09). Stratification by menopausal status indicated no association between breast cancer and hair dye use in either pre- or post-menopausal women.</td>
<td>Mendelsohn et al. (2009)26</td>
</tr>
<tr>
<td>Study Description</td>
<td>Findings</td>
<td>References</td>
</tr>
<tr>
<td>----------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>Hospital based case-control study in the UK. There were 191 cases and 561 age matched controls. 73 cases and 213 controls had ever used hair dyes.</td>
<td>A non-statistically significant increase in the relative risk of breast cancer in women who ever used hair dyes, compared with never used hair dyes (RR=1.01). There was no evidence of an increasing risk for breast cancer with increasing duration of use of hair dyes or with use beginning more than four or more than nine years before diagnosis.</td>
<td>Kinlen et al. (1977)</td>
</tr>
<tr>
<td>Hospital based case-control study in Canada and London. There were 85 cases and 170 controls, both over two locations.</td>
<td>A non-statistically significant increase in the odds of breast cancer in women who ever used hair dyes, compared with never used hair dyes (London: RR=1.3; 95% CI, 0.6-2.50 and Toronto, Ontario: RR=1.1; 95% CI, 0.5-2.4). Further statistical analyses, allowing for smoking habits, family history of cancer and age at first birth, showed no significant relationship between hair-dye use and breast cancer incidence.</td>
<td>Stavraky et al. (1979)</td>
</tr>
<tr>
<td>Hospital based case-control study in New York City with 398 cases and 90 randomly selected, age-matched controls.</td>
<td>No increase in the odds of breast cancer in women who ever used hair dyes, compared with never used hair dyes (OR=0.8; 95% CI 0.6-1.1). There was also no statistically significant difference between those who report using hair dyes at least once and those who reported more than 100 uses.</td>
<td>Koenig et al. (1991)</td>
</tr>
<tr>
<td>Hospital-based case-control study in Iran with 526 newly diagnosed breast cancer cases and 526 randomly selected, age-matched controls.</td>
<td>Multiple factors contribute to the risk of breast cancer, such as hair coloring, stress, and smoking. The OR of breast cancer from hair dye use on a regular basis compared to no use was 1.93 (95% CI, 1.41-2.62).</td>
<td>Dianatinasab et al. (2017)</td>
</tr>
</tbody>
</table>

References


28. Stavraky KM, Clarke EA, and Donner A. Case-control study of hair dye use by patients with


41. Altekruse, S. F., Henley, SJ, and Thun, MJ. Deaths from hematopoietic and other cancers in


Comments on the CIR Expert Panel document "Hair Dye Epidemiology" with reference to Breast Cancer Risk

Luigi Naldi
Centro Studi GISED, Bergamo
Unità complessa di Dermatologia,
Ospedale san Bortolo, Vicenza (Italy)

Background
Taking skin cancer aside, breast cancer is the most common cancer diagnosed in women worldwide. Established risk factors are family and personal history of breast cancer, presence of specific mutations to certain genes, such as BRCA1 or BRCA2, indicators of prolonged, increased exposure to endogenous oestrogens, such as early menarche and late menopause, and factors affecting the final cell differentiation of breast tissue, including age at first birth, number of full-term pregnancies, and duration of breastfeeding, all inversely correlated with breast cancer risk. Other recognised and modifiable risk factors, such as alcohol consumption, smoking, low physical activity, obesity, oral contraceptive exposure, hormone replacement therapy, ionizing radiation, and night shift working, increase the risk of breast cancer only marginally. However, since these factors are largely prevalent in the population, their population-attributable risk may be far from negligible [1].

Data linking breast cancer with exposure to chemicals, consumer products, or pollutants are limited and mostly inconclusive. In principle, chemicals may act through endocrine activity (e.g., bisphenol A, certain dioxin-like compounds), genotoxicity (e.g., heterocyclic amines) or even epigenetic influences. Noteworthy, the effect could be highly sensitive to the timing of the exposures [2,3].

Analysis of the studies presented in the CIR Expert Panel document on hair dye and breast cancer
The document of the Expert Panel presents data from seven papers dealing with hair dye exposure and breast cancer, including 5 case-control studies [4-8], one cohort study [9], and one systematic review [10]. Three of the case-control studies were also evaluated in the systematic review and will not be specifically considered in my assessment [4-6].

The systematic review summarises results of studies conducted from 1966 up to January 2005, and includes 12 case-control studies, which involved a total of 5019 cases and 8486 controls, and two cohort studies which recruited a total of 1135 incident cases of breast cancer [10]. Both fixed- and random-effect summary estimates were calculated, the latter being the preferable measure in the presence of significant heterogeneity as is the case of the studies considered in the systematic review. The pooled relative risk (RR) was close to 1 and nonsignificant when comparing ever use vs never use of hair dyes. When considering intensive exposure, however, defined as more than 200 lifetime exposures, the random effect estimate of RR, while not significant, raised to 1.33 (95% confidence interval, CI 0.69-2.56). No significant increased risk was documented when restricting analyses to the use of permanent dyes only. Different variables were considered for adjustment in different studies, mostly including age, smoking, and gynecological history. It should be noted
that, giving the largely prevalent use of hair dyes in the population, frequency of use rather than simple distinction between users and nonusers, would be relevant to consider.

After the above mentioned systematic review was published, data from three additional studies were made available, all being discussed in the CIR Expert Panel document. In a cohort study conducted in the framework of the Shanghai Women's Health Study, a total of 75221 women completed a baseline survey between 1996 and 2000 and were followed up to December 2005 [9]. A total of 358 incident cases of breast cancer were identified. In the sample, 29076 women (39.6%) reported ever using hair dye. The RR for breast cancer in hair dye users vs nonusers, adjusted by age, education and smoking, was 0.93 (95% CI, 0.78-1.09). No relation was documented between duration of hair dye use and risk of cancer. These data are reassuring. However, limited questions were asked about hair dye use, with no information on the type of hair dye used (permanent vs semipermanent) nor about the frequency of use. Moreover, exposure was assessed over the 3 years preceding the baseline interview only. Hence women exposed in the past, but not over the last 3 years, were classified as nonusers, a potential misclassification which, in the presence of an association, may tend to minimize it regardless of whether the association is positive or negative (i.e., bias toward the null).

In a case-control study conducted in the metropolitan New York City area and in ten counties in New Jersey (NJ), involving both African Americans and White women, breast cancer cases were identified by multiple sources, including hospital charts and NJ cancer registry [7]. Community controls were selected matched on age and race with cases. A total of 2,280 cases and 2,005 controls were enrolled. The use of hair products, including hair dyes, chemical relaxers/straighteners, and conditioning creams was assessed by a questionnaire. Data on hair dyes included the age of starting use, the typical annual frequency of use, the typical shade adopted, the typical application modality (e.g., home-kit vs salon), total duration in years of use. Potential confounders were selected based on a p-value criterion (p<0.10). Final odds ratio(OR) estimates were adjusted by age, education, body mass index, family history of breast cancer, and oral contraceptive use. In the control group, about 30% of African Americans and 58% of Whites reported regular use of hair dyes. Overall, ever use of hair dyes and duration of use were not significantly associated with increased cancer risk in both African Americans and Whites. Among African Americans, an increased risk of breast cancer was documented for the use of dark hair dye shades, and for salon application of dyes, adjusted OR being 1.51 (95% CI, 1.20-1.9) and 1.26 (95% CI, 1.00-1.58), respectively. In Whites, an increased risk was documented for dual use of relaxers and hair dyes with OR 2.40 (95% CI 1.35-4.27), the wide confidence interval reflecting the limited number of exposed women. When considering the estrogen receptor status of cancer, the risk of estrogen positive breast cancer was increased in African Americans with a higher frequency of hair dye use (OR 1.36, 95% CI, 1.01-1.84) and in Whites with the use of dark hair dye shades (OR 1.54, 95% CI, 1.01-2.33). These differences in risk profile between African Americans and Whites are not easy to reconcile. They may reflect different patterns of use. They may also represent chance effects due to multiple testing. Replication of results by an independent study is needed. Ideally, such a study should be able to ascertain the type of hair dye product used and its timing of use.

A population based case-control study in Finland recruited a total of 6,567 breast cancer patients diagnosed between 2000 and 2007 and 21,598 age-matched controls. The recruitment of patients was based on a nation-wide cancer registry covering almost 100% of solid tumors [8].
The exposure of primary interest was the use of hair dyes with detailed information on the cumulative lifetime number of hair dye episodes, age at first use, and the types of dyes used, classified as temporary, semi-permanent, permanent, “bleach,” and partial. When calculating ORs, potential confounding factors, namely parity, age at first birth, family history of breast cancer, menarche age, use of hormonal contraceptives, physical activity, alcohol use, BMI and education, were included in a stepwise regression model. Bias-adjusted ORs were calculated as well. A large proportion of women reported ever use of hair dye products, with rates increasing from 84% in women born before 1950 up to 92% in women born in or after 1960. The odds of breast cancer was significantly increased when comparing ever vs never users of hair dyes (OR 1.23, 95% CI: 1.11–1.36). The OR increased significantly with the increase in number of reported hair dye episodes, from 1.07 with 1–2 dye episodes up to 1.31 for 35–89 dye episodes. Early age at first dye (20–29 years) was associated with higher odds of breast cancer when compared to late age at first dye (40 years or later) (OR 1.14, 95% CI: 1.05–1.25). When considering ever use vs no use, the ORs were increased with all the different types of hair dyes, the highest estimates being obtained for women who reported to have used temporary and/or semi-permanent dyes, ORs being 1.32 (95% CI: 1.16–1.52) and 1.31 (95% CI: 1.17–1.46), respectively. Latency of effect was suggested by the fact that the OR for cumulative hair dye use was the highest among women born between 1950 and 1959.

Strengths of the epidemiologic studies include evaluation of a variety of populations, including those with exposure to dark hair colors. Limitations of some of the studies are lack of specificity for type of hair dyes used (oxidative versus non-oxidative) and details on color, type, or duration of use. In addition, formulations have changed over time, and they differ based on the region of the world in which they are produced and sold. Hence the specific product used and the timing of use should be better considered.

Concise summary statements
The available evidence linking hair dye use and breast cancer is limited, but warrants further investigations.
Based on the available human evidence, personal use of hair dyes is unlikely to be an important risk factor for breast cancer. However, of particular concern, are two recent studies pointing to an increased risk in different ethnic groups and populations, African Americans, White American women, Finnish women.
As a short term action, I would suggest to conduct a systematic review incorporating the evidence from the most recent studies.

References